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Survival in esophageal cancer patients with
hematogenous distant organ metastases
Objective: Esophageal cancer is a rapidly progressive cancer. In the majority of patients local
invasion or distant metastasis may be present at the time of diagnosis. The present study reviewed
the records of esophageal cancer patients with hematogenous distant organ metastases with the
aim of reporting primary tumor location, histological type, location of metastases, and survival
rates, according to treatment administered.
Method: Distant organ metastasis was detected in 50 of 316 consecutive patients that presented to
the Thoracic Surgery Department of Atatürk University between 2002 and 2007. Patient age and
gender, tumor location, history of esophagectomy, metastasis organ, treatment type, and survival
outcome were retrospectively reviewed.
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Results: The liver was the most common organ of distant metastasis and was observed in 24
(38.7%) patients, followed by lung metastasis, which was observed in 21 (33.9%) patients. Bone
metastases were detected in 5 patients, pancreatic metastases in 4, pleural metastases in 2, and
metastasis in the spleen, peritoneum, kidney, adrenal gland, brain, and diaphragm were each
observed in 1 patient. Nine patients had metastases in more than 1 organ. Overall, 6-month
survival was 58%, 1-year survival was 28%, and 2-year survival was only 2%. Mean survival was 7.8
months in patients with isolated liver metastases (range: 1-18 months) versus 7.1 months (range:
2-14 months) in patients with isolated lung metastases. Mean survival was 6.2 months (range: 132 months) in patients with multiple organ metastases, versus 7.6 months (range: 1-18 months) in
those with metastasis in 1 organ. Mean survival was 7.7 months (range: 1-18 months) in patients
that received chemotherapy, as compared to 7.1 months (range: 1-32 months) in those that did
not. Overall, mean survival was 7.3 months in patients with hematogenous distant organ
metastases.
Conclusion: Our results show that survival rates in esophageal cancer patients with distant organ
metastases were similar in those that received and did not receive chemotherapy. Thus, we
consider that new therapeutic protocols are required for metastases of esophagus carcinoma.
Key Words: Esophageal cancer, metastasis, survey

Hematojen uzak organ metastazlı özofagus kanserinde sağkalım
Received: July 03, 2008
Accepted: February 10, 2009

Correspondence
Atila TÜRKYILMAZ
Department of Thoracic Surgery
Faculty of Medicine,
Atatürk University,
25240 Erzurum - TURKEY
atilat@atauni.edu.tr

Amaç: Özofagus kanseri en hızlı progresyon gösteren kanserlerden biridir. Birçok hasta tanı
aldığında lokal yayılım veya uzak metastaz bulunabilmektedir. Bu çalışmada hematojen yolla uzak
organ metastazı saptadığımız özofagus kanserli hastaları yeniden gözden geçirerek primer tümör
lokalizasyonu ve histolojik tiplere göre metastazların dağılımı ile metastaz lokalizasyonu ve
uygulanan tedaviye göre survey sonuçları hakkında bilgi elde etmeyi amaçladık.
Metod: 2002 ve 2007 yılları arasında Atatürk Üniversitesi Tıp Fakültesi Göğüs Cerrahisi Kliniği’ne
başvuran özofagus kanserli 50 hastada uzak organ metastazı tespit edildi. Hastaların yaşı, cinsiyeti,
tümörün lokalizasyonu, histolojik tipi, özofajektomi öyküsü, metastaz organı, tedavi şekli, survey
sonuçları retrospektif olarak yeniden gözden geçirildi.
Sonuçlar: Karaciğer 24 (% 38,7) hasta ile en çok görülen uzak metastaz organıydı. İkinci olarak 21
(% 33.9) hastada akciğer metastazı tespit edildi. 5 hastada kemik metastazı, 4 hastada pankreas
metastazı, 2 hastada plevral metastaz ve birer hastada dalak, periton, böbrek, surrenal, beyin ve
diafragma metastazı tespit edildi. 9 hastada birden fazla organda metastaz mevcuttu. Genel olarak
6 aylık survey % 58, bir yıllık survey % 28, 2 yıllık survey ise sadece % 2 idi. İzole karaciğer
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metastazında ortalama survey 7,8 ay (1-18 ay arası), izole akciğer metastazında 7,1 ay idi (2-14 ay
arası) idi. Multipl organda metastazı olanlarda ortalama survey 6,2 ay (1-32 ay arası), tek organ
metastazı olanlarda ise ortalama survey 7,6 ay idi (1-18 ay arası). KT alan hastalarda ortalama
survey 7,7 ay (1-18 ay arası), almayan hastalarda ise 7,1 ay idi (1-32 ay arası). Genel olarak
hematojen yolla uzak organ metastazı yapmış hastalarda ortalama survey ise 7,3 ay olarak
hesaplandı.
Tartışma: Elde ettiğimiz sonuçlar uzak organ metastazı bulunan özofagus kanserli hastalarda
survey oranlarının farklı metastaz organlarında ve kemoterapi alan veya almayan hastalarda
birbirine yakın olduğunu göstermektedir. Özofagus kanserinin metastazlarında yeni tedavi
protokollerine ihtiyaç olduğunu düşünüyoruz.
Anahtar Sözcükler: Özofagus kanseri, metastaz, sağkalım

Introduction
Esophageal cancer ranks sixth in prevalence
among all cancers worldwide. About 386,000 people
per year die of esophageal cancer (1,2). Esophageal
cancer is one of the most rapidly progressive and
difficult to treat diseases. Regional lymph node
involvement or distant organ metastasis may
develop rapidly in this disease, with early and rapid
spread to the esophageal wall and adventitia. In
about 75% of patients local invasion, distant
metastasis, or both may be observed at the time of
diagnosis (3,4). Despite aggressive treatment,
detailed 5-year survival is only as high as 20%. In the
majority of patients, both locoregional recurrence
and distant metastases develop following esophageal
resection (3,4).
Esophageal cancer spreads in 3 ways: direct
invasion, and via lymphatic or hematogenous
routes. Most metastases in esophageal cancer cases
are to the lymph nodes. Distant organ metastases in
patients with esophageal cancer may vary,
depending on location of the primary tumor and
histological type. In the current study our aim was to
assess the survival rates in esophageal cancer
patients with hematogenous distant organ
metastases, according to location, histological type
of the primary tumor, location of metastases, and
the treatment administered.
Materials and Methods
Medical records of 50 consecutive patients that
presented to the Thoracic Surgery Department of
Atatürk University between 2002 and 2007 in whom
distant organ metastases were observed were
416

retrospectively reviewed. Patient age and gender,
tumor location, histological type, history of
esophagectomy, organ of metastasis, type of
treatment, and survival outcomes were reviewed.
Metastases were detected in the patients with
computerized tomography (CT), ultrasound
examination (US), magnetic resonance imaging
(MRI), bone scanning, and, in some patients,
histological examination. Patients with lymph node
metastases in the cervical/supraclavicular, thoracic,
and abdominal regions, and locoregional recurrence
were excluded from the study. Diagnoses of
metastases were made during surgical exploration in
4 patients that were not diagnosed with metastasis
following preoperative radiological examinations,
and in all 4 cases surgery was terminated.
Results
Of the 50 esophageal cancer patients with
hematogenous distant metastases 25 (50%) were
female and 25 (50%) were male. Mean age was 59.0
years (range: 28-79 years). Tumor location included
the upper esophagus in 4 (8%) patients, midthoracic esophagus in 22 (44%), and distal
esophagus in 24 (48%). Histological type was
squamous cell carcinoma in 38 (76%) patients and
adenocarcinoma in 12 (24%). The liver was the most
common organ of distant metastases, which
occurred in 24 (38.7%) patients, followed by lung
metastases in 21 (33.9%). Bone metastases were
detected in 5 patients, pancreatic metastases in 4,
pleural metastases in 2, and metastasis of the spleen,
peritoneum, kidney, adrenal gland, brain, and
diaphragm was each observed in 1 patient. In all, 9
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patients had metastases in more than 1 organ (liver
and lung metastases in 6 patients, bone and pleura
metastases in 1, lung, liver, and bones in 1, and
lungs, diaphragm, pleura, and adrenal gland in 1)
(Table 1).
Table 1. Distribution of hematogenous distant organ metastases in
the patients with esophageal carcinoma.
Metastatic organ

n

%

Liver
Lung
Bones
Pancreas
Pleura
Spleen
Peritoneum
Kidneys
Adrenal gland
Brain
Diaphragm

24
21
5
4
2
1
1
1
1
1
1

38.7
33.9
8.1
6.5
3.2
1.6
1.6
1.6
1.6
1.6
1.6

TOTAL

62

100

The most common organ of metastasis was the
liver, followed by the lungs, regardless of primary
tumor location (upper, middle, or lower esophagus).
Metastases in other abdominal organs usually
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originated from tumors in the distal esophagus
(Table 2).
When hematogenous distant organ metastases
were evaluated according to histological type, the
most common metastasis in squamous cell
carcinomas was to the liver, followed by the lungs in
adenocarcinomas, whereas metastasis into the liver,
lungs, and pancreas was equal. In all of the 4 patients
with pancreatic metastases, histological type was
adenocarcinoma (Table 3).
Of the 50 patients with distant organ metastases,
15 (30%) (7 with liver metastases, 3 with lung
metastases, 2 with liver-lung metastases, 1 with bone
metastasis, 1 with kidney metastasis, and 1 with
liver-lung-bone metastases) were deemed
inoperable and received chemotherapy. The
chemotherapy protocol consisted of cisplatin and 5FU in 12 patients, cisplatin, 5-FU, and epirubicine in
1 patient, cisplatin, 5-FU, and leucovorin calcium in
1, and a combination of cisplatin and etoposide in 1.
In all, 35 (70%) of the 50 patients underwent stent
replacement for palliation; none of these patients
underwent resection.
Overall, 6-month survival was 58%, 1-year
survival was 28%, and 2-year survival was only 2%

Table 2. Distribution of hematogenous metastases according to
primary tumor location.

Table 3. Distribution of hematogenous metastases according to
histological type in esophageal carcinoma patients.

Tumor location

Metastatic organ

n

%

Histological type

UPPER

Liver
Lung
Bones

2
1
1

50
25
25

MIDDLE

Liver
Lung
Bones
Kidney
Pleura

11
10
4
1
1

40
37
15
4
4

LOWER

Liver
Lung
Pancreas
Spleen
Adrenal gland
Peritoneum
Brain
Diaphragm
Pleura

11
10
4
1
1
1
1
1
1

36
33
13
3
3
3
3
3
3

Metastatic organ

n

%

Liver

20

44.5

Lung

17

37.8

SQUAMOUS

Bones

5

11.1

CELL

Kidney

1

2.2

Pleura

1

2.2

Brain

1

2.2

Liver

4

23.5

ADENOCARCINOMA

Lung

4

23.5

Pancreas

4

23.5

Spleen

1

5.9

Adrenal gland

1

5.9

Peritoneum

1

5.9

Diaphragm

1

5.9

Pleura

1

5.9
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(Figure). Mean survival was 7.8 months in isolated
liver metastases cases (range: 1-18 months) versus
7.1 months (range: 2-14 months) in cases of isolated
lung metastases. Mean survival was 6.2 months
(range: 1-32 months) in patients with multiple organ
metastases and 7.6 months (range: 1-18 months) in
those with metastasis in 1 organ. Mean survival was
7.7 months (range: 1-18 months) in patients that
underwent chemotherapy, as compared to 7.1
months (range: 1-32 months) in those that did not.
Mean survival was 7.3 months in the patients with
hematogenous distant organ metastases.
Series

94%

survival (%)

72%
58%
28%
2%
2 months

4months

6 months

12 months 24 months

time

Figure.

Survival rates in patients with esophageal cancer that
metastasized via the hematogenous route.

Discussion
Esophageal cancer is known to have an
aggressive course. Local infiltration, adjacent lymph
node involvement, and hematogenous distant organ
metastases are common. Most patients with
esophageal cancer die within 1 year of diagnosis.
Only 8%-20% of patients survive for 5 years. In the
majority of these patients the primary cause of death
is metastasis (3-5).
The most common therapy for patients in the
early stages of esophageal cancer is esophagectomy.
Some patients, however, may relapse with metastatic
disease, even though no metastases were observed at
the time of primary surgery and despite
chemotherapy. Furthermore, detailed survival
following planned curative surgery does not exceed
25% and disease-free survival is only 12 months (5).
This could be due to the presence of
micrometastases or metastases that are not detected
during surgery (6). Depth of tumor invasion is
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considered the most important predictor of
postoperative recurrence (7).
Appropriate staging of esophageal carcinoma
based on BT and endoscopic US examination will
preclude unnecessary surgery. PET provides more
accurate data than BT for detecting distant
metastases. With the standard diagnostic strategy,
however, more than 30% of distant metastases are
radiologically occult and surgery is still performed in
a substantial number of patients with distant
metastases (8). This highlights the fact that current
staging methods alone fail to identify disseminated
tumor cells. Thus, sensitive molecular processes are
being developed to identify disseminated tumor cells
in the lymph nodes and distant organs (9).
The metastatic process consists of several steps
that are quite organized and organ-selective (10,11).
Early metastatic relapse following complete
resection of a localized tumor suggests disseminated
tumor cells or micrometastases that could not be
detected with routine imaging methods during
surgery. The first step of the metastatic cascade
consists of tumor cell adhesion loss, induction of
cellular motility, and local tumor cell invasion (12).
These steps are followed by dissemination to
regional lymph nodes or hematogenous circulation.
In this case, the tumor reaches secondary organs via
immovable or dormant cells. Some of these cells
may be precursors of metastases that may appear
several years after curative resection of the primary
tumor.
Two histopathological types are most commonly
seen in esophageal carcinoma. A high recurrence
rate and the fact that recurrence is predominant in
patients with tumors of the lower third of the
esophagus suggest biological differences between
adenocarcinomas and squamous cell carcinomas
(7). Esophageal adenocarcinoma tends to grow
locally. It may lead to invasion to adjacent organs,
causing local complications, and may lead to death.
Invasion into the periadventitial tissue, esophageal
muscle layer, and adjacent tissues is seen in about
80% of patients, whereas lymphatic spread occurs in
70% of patients (13). In particular, metastases into
the mediastinal, abdominal, and cervical lymphatic
ganglia are common. Lymphatic spread with
submucosal invasion is responsible for intra-
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esophageal tumor growth. Hematogenous spread is
less common and is seen later in these cancers (13).
The most common sites of hematogenous
metastases in esophageal cancer cases are the liver,
lungs, and bones (14). In the present study most
hematogenous metastases were observed in these
organs. Rarely, hematogenous spread into other
various organs may be seen; its incidence, however,
is about 1%-2%. These organs include the brain,
spleen, pancreas, stomach, kidneys, adrenal gland,
peritoneum, pleura, diaphragm, and chest wall (1517). It has been noted that there is a tendency for
hematogenous recurrence in esophageal cancer,
especially in cases of negative E-cadherin in liver
and lung metastases (18). As for lymphatic
recurrence, the hematogenous type also significantly
correlates with positive node sites and number
(15,18). Although liver metastases were more
common in adenocarcinoma cases than in cases of
squamous cell carcinoma in a study by Quint et al.
(15), liver metastases were more common in cases of
squamous cell carcinoma than in adenocarcinoma
cases in the present study (44.5% and 23.5%,
respectively). Furthermore, in the present study
hematogenous metastases were most common in the
liver, followed by the lungs in esophageal cancers in
which the primary tumor was located in the upper,
middle, or lower esophagus.
Systemic metastases are seen in about 25% of
patients within 20 months of curative resection.
Patients with metastatic esophageal carcinoma have
a poor prognosis due to their general medical status;
therefore, these patients usually cannot tolerate
aggressive medical treatment. Even palliative
surgery to relieve dysphagia may result in high
morbidity rates in these patients. Resection may be
performed in rare cases in metastatic patients.
Resection criteria are as follows in cases of
metastatic disease (19): functional status of the
patient must be good, no local recurrence of the
primary tumor, well-limited solitary metastasis,
tumor must be completely resected without
significant dysfunction, and at least 1 year must have
elapsed from the time of initial treatment of the
primary esophageal carcinoma.
Patients with distant organ metastases usually
have a poor general medical status at the time of
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presentation and receive only palliative treatment.
Squamous cell carcinoma of the esophagus is known
to respond well to chemotherapy. Standard
treatment for liver metastases of the distal esophagus
and cardia adenocarcinomas is chemotherapy (20).
Systemic chemotherapy is still considered the most
common standard treatment for patients with
distant organ metastases. Nakada et al. (21) reported
that they achieved complete response with
chemotherapy consisting of 5-fluorouracil and
cisplatin in a patient with esophageal cancer and
liver metastasis. Sueyama et al. (22) achieved
survival for more than 3 years with cisplatin and
continuous 120-h 5-fluorouracil infusion in an
advanced esophageal cancer patient with lung and
liver metastases. Uchikado et al. (23) reported that
treatment with low doses of 5-fluorouracil and
cisplatin was quite successful in a patient with
adenosquamous carcinoma of the esophagus with
liver metastasis, and reported that successful
outcomes could be achieved with the same
chemotherapy protocol in patients with esophageal
cancer and visceral metastasis. In randomized trials,
however, the duration of response was short and
mean survival was less than 1 year, although
symptoms were relieved by the chemotherapy in the
majority of patients (24). The mortality rate related
to the treatment was high, even in a series in which
the response rate was 35% in patients with
metastatic esophageal carcinoma in response to a
combination of 5-fluorouracil and cisplatin.
Therefore, no standard treatment regimen exists for
metastatic esophageal carcinoma. High tumor
burden, advanced age, smoking, alcohol
consumption, and comorbid conditions reduce the
tolerance to toxic chemotherapy regimens in
patients with metastatic esophageal carcinoma.
Furthermore, the effect of chemotherapy on survival
is unclear. Nevertheless, chemotherapy is the most
studied treatment option for relieving symptoms
and prolonging survival. Mean survival was 7.7
months in 15 of our patients that received cisplatinbased chemotherapy and no significant
improvement was observed in survival as compared
to the patients that did not receive chemotherapy.
Hepatic arterial infusion chemotherapy, or
aggressive hepatectomy, has been performed
recently in cases of liver metastases of gastric or
419
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colorectal cancers; however, the success rate of
surgery or chemotherapy in the case of liver
metastasis in patients with esophageal carcinoma is
low. Thus, Ikeda et al. (25) propose treatment with
radiotherapy in cases of liver metastases in patients
with esophageal squamous cell carcinoma.
Kato et al. (26) reported that the 3-year survival
rate is only 0.3% in patients with esophageal cancer
and distal organ metastases. In the present study,
survival at 2 years was seen in only 1 (2%) patient (a
65-year-old woman with lung and liver metastases).
The patient had not undergone surgery for the
primary disease and she declined chemotherapy).
Mean survival in the current study was 7.3 months
in the patients with hematogenous metastases. In
the case of lung and liver metastases, mean survival
was similar in the patients that received and did not
receive chemotherapy (7.8 and 7.1, and 7.7 and 7.1
months, respectively).
In summary, hematogenous spread in esophageal
cancer most commonly occurs in the liver, lungs,
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and bones. The most common treatment is
chemotherapy. The most commonly used
chemotherapy protocol consists of cisplatin and 5fluorouracil. In metastatic patients the complete
response rate is low with chemotherapy; therefore, a
standard chemotherapy protocol has yet to be
determined for metastatic esophageal carcinoma.
Based on the results we obtained, survival rates were
similar in patients with hematogenous metastases in
different organs, whether or not they received
chemotherapy–about 6-8 months. In conclusion,
current staging techniques alone fail to detect
disseminated tumor cells. Thus, sensitive molecular
processes are required for detecting disseminated
tumor cells in distant organs at early stages.
Furthermore, chemotherapy protocols that are less
toxic and more effective at prolonging survival must
be developed. Thus, patients with distant organ
metastases may be diagnosed at earlier stages,
unnecessary surgery can be avoided, and patient
comfort and survival can be improved with
appropriate treatment combinations.
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